([mh "Clostridioides difficile"] OR [mh ^"pseudomembranous colitis"] OR ("Clostridium difficile" OR "Clostridioides difficile" OR difficile OR "pseudomembranous enterocolitis" OR "Bacillus difficilis" OR "Peptoclostridium difficile" OR ("antibiotic-associated" NEAR/2 diarrh?ea)):ti,ab,kw) AND ([mh "Immunoglobulins, Intravenous"] OR ((immunoglobulin* NEAR/6 (monoclon* OR polyclon*)) OR IVIG OR ((intravenous* or iv) NEAR/2 (antibodies or immunoglobulin* or "immune globulin" or gammaglobulin or gamma-globulin or ig)) OR bezlotoxumab OR "Flebogamma DIF" OR Gamunex OR Globulin-N OR "Globulin N" OR Intraglobin OR Gammagard OR Gamimune OR Gamimmune OR Privigen OR Sandoglobulin OR Venoglobulin OR Venoglobulin-I OR Venimmune OR Iveegam OR Alphaglobin OR Endobulin OR Gammonativ OR zinplava):ti,ab,kw)
49 results of which 46 are CENTRAL records; returns all 8 in validation set, plus another 27 records that overlap with the Embase results, plus 5 from ClinicalTrials.gov, 1 each from CINAHL and ICTRP

validation set: 10.1254/fpj.152.39 or 10.1093/jac/dky182 or 10.1093/cid/ciy171 or 10.1093/cid/cix809 or 10.1016/j.jiac.2017.10.005 or 10.1093/cid/cix523 or 10.1056/NEJMoa1602615
should return 8 trials

Cochrane trials:
("Intravenous immunoglobulin" AND "Clostridium difficile")
- Preliminary Results of a Randomized Clinical Trial of Intravenous Immunoglobulin in Solid Organ Recipients with Severe Infection and Secondary Antibody Deficiency - this is only available as a 2020 meeting abstract in J Heart and Lung Transplantation
- Potential intravenous immunoglobulin mediated protection against severe infections in a randomized clinical trial in solid organ transplantation - same journal and authors as above - 2017 meeting abstract; also in Embase (618690823), CC said it meets inclusion criteria 3/4/21
- Descriptive study of intravenous immunoglobulin for the treatment of recurrent Clostridium difficile diarrhoea
- IVIG Versus Placebo for the Treatment of Patients With Severe C-Diff - https://clinicaltrials.gov/show/NCT00177970